D

DBV Technologies S.A. (DBVT)

NCM – Real vaqt narxi. Valyuta: USD

19.60

-0.40 (-2.00%)

Bozor ochiq: May 13, 2026, 10:18 AM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

D

DBV Technologies S.A. (DBVT)

NCM – Real vaqt narxi. Valyuta: USD

19.60

-0.40 (-2.00%)

Bozor ochiq: May 13, 2026, 10:18 AM EDT

12.05.2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C.

24.04.2026

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

17.04.2026

DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue

DBV Technologies S.A. (DBVT) reported positive Phase 3 VITESSE results for Viaskin Peanut, advancing toward blockbuster sales projections exceeding $2 billion. My model estimates Viaskin Peanut's U.S. peak sales at $1.25 billion, with global revenues potentially reaching $2.1 billion, assuming central penetration and duration metrics. Current DBVT market valuation (~$2 billion) implies either lower peak sales or higher perceived risk versus a risk-adjusted valuation near $5 billion.

14.04.2026

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

DBV Technologies (DBVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

14.04.2026

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know

The mean of analysts' price targets for DBV Technologies (DBVT) points to a 79% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

02.04.2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

26.03.2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD : The 2025 annual financial report; The Board of Directors' corporate governance report (“rapport sur le gouvernement d'entreprise”) required under Article L.

Videolar

No Data

There is no data to display

Press-relizlar

02.04.2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

26.03.2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD : The 2025 annual financial report; The Board of Directors' corporate governance report (“rapport sur le gouvernement d'entreprise”) required under Article L.

26.03.2026

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Bolstered executive leadership team in preparation for BLA submission and potential approval Reported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026 —providing funding into the second quarter of 2027 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today reported financial results for the full year 2025. The consolidated financial statements are prepared under U.S. Generally Acceptable Accounting Principles (“U.S. GAAP”) and International Financial Reporting Standards (“IFRS”) for the purpose of Form 10-K and French “Document d'Enregistrement Universel” containing the Annual Financial Report – were approved by the Board of Directors on March 26, 2026.

24.03.2026

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026.

Search stocks

DBV Technologies S.A. (DBVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

DBV Technologies S.A. (DBVT)

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Videolar

No Data

Press-relizlar

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review